Nyxoah (NYXH) Projected to Post Quarterly Earnings on Thursday

Nyxoah (NASDAQ:NYXH) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 8:00 AM ET.

Nyxoah Price Performance

Shares of NASDAQ:NYXH opened at $3.94 on Thursday. Nyxoah has a one year low of $3.74 and a one year high of $11.87. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.70 and a quick ratio of 1.41. The company has a market cap of $134.20 million, a price-to-earnings ratio of -1.58 and a beta of 1.56. The firm has a 50 day simple moving average of $4.67 and a 200 day simple moving average of $5.08.

Analysts Set New Price Targets

NYXH has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nyxoah in a research note on Monday, December 29th. Stifel Nicolaus dropped their target price on Nyxoah from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Finally, Piper Sandler reissued an “overweight” rating and set a $9.00 price target (down from $12.00) on shares of Nyxoah in a research note on Friday, November 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Hedge Funds Weigh In On Nyxoah

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. boosted its holdings in Nyxoah by 35.6% in the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after acquiring an additional 3,353 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares during the period. Citadel Advisors LLC acquired a new position in shares of Nyxoah in the 3rd quarter worth approximately $98,000. Deutsche Bank AG boosted its stake in shares of Nyxoah by 40.0% in the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Shay Capital LLC acquired a new stake in shares of Nyxoah during the second quarter worth $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.